Hypatia Group seeds platform technologies to increase human healthspan, advance health equity, and enable economic prosperity (https://www.hypatiagroup.io/). We build things with creative people and invest in step-change technologies. Visit Bento Bio, our 2022 spin out...we're bringing Play to Learn (P2L) and Participate to Earn (P2E) principles to clinical trials and precision medicine, achieving global reach and unprecedented engagement IRL/web2/web3 (https://www.flare.bentobio.com/ and https://www.youtube.com/watch?v=7FbSaSIwV04)

HYPATIA VETS (B2G) is a Joint Venture formed to provide mission leaders in the public sector access to end-to-end IT services (IaaS, PaaS, DaaS, ZTA, ConMon, PenTesting, 2TM, Takeback) and cutting edge solutions with emerging technologies (AIML, Quantum, AR/VR, Web3, LEO Comms). With top secret facilities and deep bench of science and engineering talent, we provide system design, software development, cloud services, cybersecurity, operations and maintenance. We provide an easy button for agencies to acquire emerging technology services -- from quantum computing to artificial intelligence -- and meet their socioeconomic goals. We are SBA-Certified as WOSB & SDVOSB, registered in SAM (UEI YYAJPKWUFM39), with TS-cleared staff in JPAS, a second-touch manufacturing facility with OCONUS deployment capabilities, and VAR partnerships with the leading cloud and OEM suppliers in the world.

Hypatia Project (B2G/B2B) is the digital skunkworks of the Hypatia Group, leading code-named technology projects as a trusted innovation partner to governments and industry. We work on ‘hard problems’ at the interface of hardware, software, biology and physics, with core capabilities architecting platform technologies and implementing digital transformation solutions. Our Past Performance -- consistently ranked as exceptional -- includes building a multi-cloud software factory for artificial intelligence (DoD Joint Artificial Intelligence Center); obtaining authority to operate (ATO) for business systems cloud (Pentagon Office of the CIO); architecting Zero Trust strategy and continuous monitoring implementation plan for AI multi-cloud (Pentagon Office of the CIO); repurposing generic oncology drugs to make cancer treatment more accessible (FDA Oncology Center of Excellence); evaluating decentralized suicide prevention programs for U.S. Veterans (MITRE Corporation and Veterans Health Administration); designing consortium blockchains for public health emergency communications (FDA CDER) and vendor supply chain smart contracts (UAE Ministry of Finance & Dell Technologies); architecting and manufacturing decentralized clinical trial platform and wallet technology (Lupus Research Alliance). Additionally, have served as a Data Innovation Joint Venture Partner to the U.S. Department of Commerce, supporting complex data challenges for the US government. (http://www.hypatiaproject.com).

Launched in March 2023, FDA’s Center for Drug Evaluation and Research announced a partnership with the Lupus Research Alliance (LRA) to launch the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a first-of-its-kind public-private partnership focused on addressing challenges impacting lupus clinical trial success (read more: https://www.fda.gov/drugs/drug-safety-and-availability/fda-launches-lupus-treatment-consortium-partnership-lupus-research-alliance)

Launched the Lupus Clinical Investigators Network (LuCIN), a clinical trial implementation infrastructure comprised of 57 academic medical centers (AMDs) in the US and Canada with 200 clinical investigators and patient communities to accelerate translational science and commercialization of drugs and biologics for lupus and adjacent autoimmune disease.

Improving healthcare worldwide by helping entrepreneurs with disruptive advances in healthcare discovery and delivery (https://www.lifescienceangels.com/see-deals-we-funded).Life Science Angels (LSA) is a group of 150 accredited angel investors based in Palo Alto, CA. In August 2014, Life Science Angels was named the Top Angel Investment Group in the U.S. CB Insights recognized LSA as the best performer out of 370 angel groups analyzed nationwide based on criteria that included: historical performance, network strength (connections), selection aptitude and brand recognition.We are actively investing in medical technology and biotech, with an extensive portfolio. Typical investments range from $250k-$750k, with syndicated financings ranging from $1.5M-6M.LSA is not just angel money. We operate as a small, proactive VC firm, offering our entrepreneur partners unique value beyond financing.

I completed two terms on the LSA Board of Directors, serving as Chair of Syndication. In this role, I sourced investment opportunities, negotiated valuations and term sheets, and syndicated capital formation (Seed, A, B rounds) for new and existing LSA portfolio companies across a national network of accredited investing groups.

Launched and scaled 24/7/365 synchronous e-learning platform for Psychology business unit; created bundling alliances with textbook publishers for higher education; recruited, hired and managed global team of 18 direct reports. Acquired by Pearson (NYSE: PSO).

Designed and implemented diagnostic-prescriptive interventions, interactive games and individualized educational programs to enhance cognitive performance for 500+ children with neurodevelopmental disorders at the internationally acclaimed clinical day facility and arts-infused learning center founded by the legendary Sally L. Smith. Roles included Academic Club Leader (Lorenzo de Medici); Academic Game Designer; Liaison with Robert Rauschenberg Foundation; Game-Based Diagnostics; Sneaky Learning Interventions; Master Teacher; Author.

I collaborated with Robert Rauschenberg, Sally Smith, National Gallery of Art and Faculty to develop and execute curriculum, public art building, and training workshops for visiting artists serving communities with learning disabilities in tribal organizations, rural schools, and under-resourced urban centers. https://www.rauschenbergfoundation.org/

Managed 18 direct reports and a commercial portfolio of 1.8 million square feet and 27 acres in Washington's central business district and Northern Virginia's technology corridor, completing an in-house business management administration program in finance, accounting, contract negotiation, risk management and real estate law.